The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial
Open accessAbstract
BACKGROUND: Invasive aspergillosis is an important cause of morbidity and mortality in immunocompromised patients. Current treatments provide limited benefit. Posaconazole is an extended-spectrum triazole with in vitro and in vivo activity against Aspergillus species. METHODS: We investigated the efficacy and safety of posaconazole oral suspension (800 mg/day in divided doses) as monotherapy in an open-label, multicenter study in patients with invasive aspergillosis and other mycoses who were refractory to or intolerant of conventional antifungal therapy. Data from external control cases were collected retrospectively to provide a comparative reference group. RESULTS: Cases of aspergillosis deemed evaluable by a blinded data review committee included 107 posaconazole recipients and 86 control subjects (modified intent-to-treat population). The populations were similar and balanced with regard to prespecified demographic and disease variables. The overall success rate (i.e., the data review committee-assessed global response at the end of treatment) was 42% for posaconazole recipients and 26% for control subjects (odds ratio, 4.06; 95% confidence interval, 1.50-11.04; P=.006). The differences in response between the modified intent-to-treat treatment groups were preserved across additional, prespecified subsets, including infection site (pulmonary or disseminated), hematological malignancy, hematopoietic stem cell transplantation, baseline neutropenia, and reason for enrollment (patient was refractory to or intolerant of previous antifungal therapy). An exposure-response relationship was suggested by pharmacokinetic analyses. CONCLUSIONS: Although the study predates extensive use of echinocandins and voriconazole, these findings demonstrate that posaconazole is an alternative to salvage therapy for patients with invasive aspergillosis who are refractory to or intolerant of previous antifungal therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Self-citationEfficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Self-citationInvasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Self-citationMaertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A., Taylor, A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423381 · Cited by 658
Self-citationWalsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A., Bow, E., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 629
Self-citationEspinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2950-2956.1998 · Cited by 576
NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis
Denning, D. W., Lee, J. Y., Hostetler, J. S., Pappas, P., Kauffman, C. A., Dewsnup, D. H., Galgiani, J. N., Graybill, J. R., Sugar, A. M., Catanzaro, A., et al. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90023-x · Cited by 450
Self-citationOpportunistic Mycoses in the Immunocompromised Host: Experience at a Cancer Center and Review
Anaissie, E. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.supplement_1.s43 · Cited by 364
Marr, K. A., Patterson, T., & Denning, D. (2002) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00035-1 · Cited by 307
Self-citationAspergillus nidulans Infection in Chronic Granulomatous Disease
Segal, B. H., DeCarlo, E. S., Kwon-Chung, K. J., Malech, H. L., Gallin, J. I., & Holland, S. M. (1998) · Medicine · doi:10.1097/00005792-199809000-00004 · Cited by 263
Self-citationWalsh, T. J., Petraitis, V., Petraitiene, R., Field‐Ridley, A., Sutton, D., Ghannoum, M., Sein, T., Schaufele, R., Peter, J., Bacher, J., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/377210 · Cited by 253
Self-citationDisposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects
Krieter, P., Flannery, B., Musick, T., Gohdes, M., Martinho, M., & Courtney, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3543-3551.2004 · Cited by 212
Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.857-869.2001 · Cited by 179
Self-citationGroll, A. H., Kurz, M., Schneider, W., et al. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00496.x · Cited by 140
Voriconazole: therapeutic review of a new azole antifungal
Herbrecht, R. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.4.485 · Cited by 113
Self-citationOakley, K. L., Morrissey, G., & Denning, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1504 · Cited by 109
Oakley, K. L., Moore, C. B., & Denning, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1124 · Cited by 100
Ullmann, A. J. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001884 · Cited by 84
Barchiesi, F., Arzeni, D., Fothergill, A. W., Francesco, L. F. D., Caselli, F., Rinaldi, M. G., & Scalise, G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.226-229.2000 · Cited by 80
Efficacy of SCH56592 in a Rabbit Model of Invasive Aspergillosis
Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W., Loebenberg, D., Rinaldi, M. G., & Patterson, T. F. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.780-782.2000 · Cited by 64
Self-citationEfficacy of Posaconazole in a Murine Model of Central Nervous System Aspergillosis
Imai, J. K., Singh, G., Clemons, K. V., & Stevens, D. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.4063-4066.2004 · Cited by 59
Self-citationNajvar, L. K., Cacciapuoti, A. F., Hernandez, S., Halpern, J., Bocanegra, R. A., Gurnani, M., Menzel, F., Loebenberg, D., & Graybill, J. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.758-764.2004 · Cited by 51
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Self-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Self-citationUllmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Self-citationPosaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,345
Self-citationAntimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Metadata
- Authors
- Walsh, T. J., Raad, I., Patterson, T. F., Chandrasekar, P., Donowitz, G. R., Graybill, R., Greene, R. E., Hachem, R., Hadley, S., Herbrecht, R., Langston, A., Louie, A., Ribaud, P., Segal, B. H., Stevens, D. A., van Burik, J. H., White, C. S., Corcoran, G., Gogate, J., Krishna, G., Pedicone, L., Hardalo, C., & Perfect, J. R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01
- Volume
- 44
- Issue
- 1
- Pages
- 2-12
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2106243271
- Cited by
- 752
- References
- 23
- FWCI
- 37.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.